Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.00 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | reachable by antibody | 0.45 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | no papers tie it to Parkinson's yet | 1.00 |
| pathways Reactome | in no curated pathway | 0.00 |
No case: the score is under the bar. Receipt 15814
Sealed predictions
- MIEN1 in dopamine neurons, braak+0.22 (p 0.565) → +0.72 (p 0.029)receipt 15821
Swarm cases
receipt 15821: MIEN1 in dopamine neurons, braak
- power
- full sample +0.50 (p 0.034, n 18), 95% CI +0.04 to +0.78. the interval excludes zero: something may be there, smaller than a half can see.
- confounder
- adjusted for sex: +0.49 (p 0.037, n 18). holds up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.56 (p 0.016, n 18). not the mix.
- skeptic
- leave-one-out range +0.44 to +0.64, sign flips 0; without severely affected donors +0.50 (p 0.034, n 18). robust.
- cell type
- strongest in oligodendrocytes: +0.64 (p 0.0040, n 18) vs +0.50 in dopamine neurons. proposing oligodendrocytes.
- axis
- no measure beats "tracks Braak Lewy-body stage" for MIEN1 in dopamine neurons.
follow-up registered; not confirmed in substantia nigra, an independent cohort.
follow-up MIEN1 · oligodendrocytes · braak: substantia nigra, an independent cohort (Parkinson's or LBD vs controls) +0.38 p 0.183 (needs p < 1.5e-4)
Receipts
loading the receipts